Varenicline for Smoking Cessation in Schizophrenia: Safety and Effectiveness in a 12-Week, Open-Label Trial.

@article{Pachas2012VareniclineFS,
  title={Varenicline for Smoking Cessation in Schizophrenia: Safety and Effectiveness in a 12-Week, Open-Label Trial.},
  author={Gladys N. Pachas and Corinne Cather and Sarah A Pratt and Bettina B. Hoeppner and Johanna Nino and Sara V. Carlini and Eric D Achtyes and Harry Lando and Kim T Mueser and Nancy A. Rigotti and Donald C. Goff and A Eden Evins},
  journal={Journal of dual diagnosis},
  year={2012},
  volume={8 2},
  pages={117-125}
}
OBJECTIVES: Varenicline was approved by the FDA in 2006. In 2009, based largely on case reports, the FDA issued a warning of possible adverse neuropsychiatric effects including depression and suicidal thoughts and behavior for varenicline and bupropion. Prospective trials of varenicline have not reported increased incidence of psychiatric adverse events other than sleep disturbance, but smokers with major mental illness have been excluded from large prospective trials of varenicline to date. We… CONTINUE READING
Recent Discussions
This paper has been referenced on Twitter 2 times over the past 90 days. VIEW TWEETS
20 Citations
0 References
Similar Papers

Citations

Publications citing this paper.
Showing 1-10 of 20 extracted citations

Similar Papers

Loading similar papers…